To compare the prevalence of and association between falls and frailty of prostate cancer survivors (PCSs) who were current, past or never users of androgen deprivation therapy (ADT). DESIGN: Cross-sectional. SETTING: Mail and electronic survey. PARTICIPANTS: PCSs (N = 280; mean age 72 AE 8). MEASUREMENTS: Cancer history, falls, and frailty status (robust, prefrail, frail) using traditionally defined and obese phenotypes. RESULTS: Current (37%) or past (34%) ADT users were more than twice as likely to have fallen in the previous year as never users (15%) (P = .002). ADT users had twice as many recurrent falls (P < .001) and more fall-related injuries than unexposed men (P = .01). Current (43%) or past (40%) ADT users were more likely to be classified as prefrail or frail than never users (15%) (P < .001), and the prevalence of combined obese frailty + prefrailty was even greater in current (59%) or past (62%) ADT users than never users (25%) (P < .001). Traditional and obese frailty significantly increased the likelihood of reporting falls in the previous year (odds ratio (OR) = 2.15, 95% CI = 1.18-3.94 and OR = 2.97, 95% CI = 1.62-5.58, respectively) and was also associated with greater risk of recurrent falls (OR = 3.10, 95% CI = 1.48-6.5 and OR = 3.99, 95% CI = 1.79-8.89, respectively). CONCLUSIONS: Current and past exposure to ADT is linked to higher risk of falls and frailty than no treatment. PCSs should be appropriately counseled on fall prevention strategies, and approaches to reduce frailty should be considered.
P
rostate cancer is the most common cancer in men and strikes predominantly in older age.
1 Forty-five percent of all prostate cancer survivors (PCSs) will receive treatment with androgen deprivation therapy (ADT) as part of their primary therapy, for biochemical recurrence, or because of metastatic spread. 2 ADT is associated with serious adverse consequences that might increase rates of falls, [3] [4] [5] [6] frailty, 3 and dysfunction 3, 7 and contribute to morbidity and mortality from noncancer causes. Recent development of higher-potency inhibitors of androgen signaling is rapidly expanding the use of ADT, 4, 6, 8, 9 accelerating the urgency to mitigate serious, life-altering side effects of these drugs.
Falls and falls-related injuries are the costliest and most life-threatening injuries in older persons, resulting in age-related fractures, traumatic brain injury, internal organ damage, hospitalization, disability, and death. 10, 11 ADT may accelerate physical changes that older adults experience that are conceptualized as frailty-a cycle of inactivity, slowing, and weakening that cascades into falls, dysfunction, and disability. The frailty phenotype, a cluster of five components (shrinking, weakness, slowness, exhaustion, inactivity), is a way to quantify frailty and is predictive of hospitalization, development of disability, and falls in older adults without cancer. 12, 13 ADT is associated with development of individual frailty components, including muscle loss, 14, 15 weakness, 7 fatigue, 16 slow walking speed, 7, 16 and inactivity. 17, 18 Although traditionally conceived as a wasting disorder, there is increasing recognition of the contribution of obesity to negative health outcomes similar to those of frailty, and thus some have proposed an obese frailty phenotype, substituting obesity for shrinking. 17 Because ADT is also linked with excess fat gain, 18 androgen-deprived men may also be at risk of obese frailty.
The goals of this study were to better describe the prevalence of and associations between ADT use, falls, and frailty. Because it is thought that limited or intermittent courses of ADT may minimize side effects while maintaining therapeutic efficacy, fall and frailty rates of current and past users of ADT were also compared. It was hypothesized that fall and frailty rates would significantly differ according to ADT use (current, past, never), with rates being highest in current users, lowest in never users, and intermediate in past users. It was further hypothesized that, independent of demographic variables (e.g., age) and clinical history (e.g., disease severity), ADT use would be significantly associated with frailty in PCSs and that ADT use and frailty would each be significantly associated with falls in PCSs.
MATERIAL AND METHODS
The Oregon Health & Science University institutional review board approved the study and procedures. All men consented to participate in the study before completing the survey.
Study Design and Sample
Men were identified through a search of hospital tumor registry of individuals with a prostate cancer diagnosis within the last 10 years (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) , and a survey was mailed electronically or by post to potentially eligible men (N = 909). Based on his use of ADT, confirmed through the electronic health record, a man was categorized as a never, current (dose received ≤12 months), or past (no treatment for >12 months) user of ADT.
Data Collection
Men completed a questionnaire about their demographic characteristics, cancer and treatment history, falls history, and frailty status. Falls over the last year were determined using an accepted and standardized definition. 19 If a man reported one or more falls, he was considered to be a faller, with further classification as a single faller if he reported having only one fall or a recurrent faller if he reported two or more falls. For fallers, follow-up questions were asked about fall number and injuries. Frailty was assessed using the self-report FRAIL scale to ascertain the presence of five frailty criteria: fatigue, resistance, ambulation, illness, and loss of weight to categorize men as robust (0 criteria), prefrail (1-2 criteria), and frail (≥3 criteria). 20 The International Association of Aging recommends the FRAIL scale as a simple, scalable method of assessing frailty in large groups of people and accurately predicting frailty in community samples. [20] [21] [22] The weight loss criterion (>5% of loss of body weight in the past year) is the measure for the traditional frailty component of "shrinking," an indicator of sarcopenia. Although ADT is associated with muscle loss, it is associated with a proportionately greater gain of fat mass 18 that may contribute to morbidity 23 and fall risk. 24 Thus, as has been done previously, frailty was also recategorized into an obese frail phenotype, substituting obesity (body mass index (BMI) > 30.0 kg/m 2 ) for the weight-loss criterion. 3 
Statistical Analysis
To compare the incidence of falls and prevalence of frailty components of ADT exposure groups, Pearson chi-square tests were conducted on categorical variables (e.g., 0 vs 1 vs ≥2 falls; frailty components) and analyses of variance on continuous variables (e.g., number of falls). Characteristics of PCSs associated with falls and frailty were identified using multinomial logistic regression and logistic regression models. Relevant clinical and demographic variables were included as control variables. Multinomial logistic regression allowed those who reported no falls to be compared with those who reported one or two or more falls and those who were robust to be compared with those who were prefrail or frail for the traditional and obese frailty phenotypes. When used as a predictor, frailty was limited to robust versus any frailty because of sample size restrictions because no participants who were frail had only one fall. Logistic regression was used to compare no falls with any falls and robust with any frailty. Significance was set at P < .05, and odds ratios (ORs) with 95% confidence intervals (CIs) were used to quantify effect size.
RESULTS
Of 909 mailings to potentially eligible participants, 318 were completed the survey, a response rate of 35%. Only the date of cancer diagnosis was available on all potentially eligible participants. Survey respondents did not significantly differ in their average time since diagnosis (mean 5.0 AE 2.7 years) from men who did not respond (5.3 AE 2.4 years) (P = .15). Only men who provided consent to access their electronic health records to verify cancer-related information were included in the analyses (n = 280). The median age of the sample was 71 (range 49-94); never ADT users were slightly younger than current and past users (Table 1) . Current and past users had a higher BMI, with more than twice the proportion of men classified as obese compared to never users. Never users were more likely to have undergone surgery but less likely to have had radiation therapy than current and past ADT users. Current ADT users had the highest rates of metastatic disease, and past and never users had a similar extent of disease.
More than twice as many current (37%) and past (34%) ADT users had had one or more falls in the past year than never users (15%), with ADT users having four times the rate of recurrent falls (≥2 falls) of never users (P < .001; Table 2 ). ADT users had significantly more falls resulting in injuries than never users (P = 0.011) and experienced more bruises, scrapes, and fractures related to their fall.
When using the traditional frailty phenotype, a significantly higher proportion of current (40%) or past (43%) ADT users were classified as prefrail or frail than of never users (15%) ( Table 3 ; P < .001), with more than twice the rate of prefrailty and 10 times the rate of frailty. The prevalence of obese prefrailty and frailty was even greater and was significantly different between current (59%) or past (62%) ADT users and users (25%) (P < .001). Significantly more ADT users met the frailty criteria of ambulation, resistance, fatigue, and obesity than of never users.
To isolate the independent contribution of ADT use to falls and frailty in addition to that of disease severity, other treatments, and age, all regression models were adjusted for these factors. Table 4 illustrates the contribution of ADT use to phenotypes of traditional and obese frailty. Current and past ADT exposure were associated with nearly three times the odds of any frailty as no exposure (P < .05). The prevalence of frailty did not significantly differ between current and past ADT users. ADT exposure increased the odds of any frailty (P= .06 to P = .10), with frailty rates nine times as high in ADT users as in never users. When using the obese frailty phenotype, the odds of having obese prefrailty and obese frailty were 3-19 times as high in current or past ADT users than never users (all P < .05). Table 5 illustrates the contribution of ADT and frailty (traditional and obese phenotypes) to the risk of falls. After adjustment for disease status and other confounders, the odds of being a faller (≥1 falls) was statistically significantly higher for ADT users, with ADT exposure associated with a 5-times higher likelihood of having recurrent falls in the past year than for men not exposed to ADT (P < 0.01). Traditionally defined frailty significantly increased the likelihood of being a faller (OR = 2.15; 95% confidence interval (CI) = 1.18-3.93) or a recurrent faller (OR = 2.97, 95% CI = 1.62, 5.59) but did not increase the odds of a single fall. When replacing traditional frailty with obese frailty as a predictor variable, the likelihood of being a faller or recurrent faller increased by 50%. 
DISCUSSION
Consistent with the hypotheses, this study suggests that ADT may lead to recurrent and injurious falls that could be explained in part by worsening frailty; but contrary to the expectation that fall risk would lessen if ADT were stopped, fall rates of current and past users of ADT were similar. ADT users were more than twice as likely to have some degree of frailty than men not on ADT, using traditional frailty criteria developed and validated in older adults. Rates of frailty are substantially higher in ADT users when using a contemporary frailty phenotype that considers obesity in lieu of sarcopenia as a frailty criterion. As with falls, past ADT users had frailty rates similar to those of current ADT users, suggesting little reversal of ADT side effects with discontinuation. Unsurprisingly then, development of traditional or obese frailty was associated with a significantly higher risk of being a faller or recurrent faller. Men exposed to ADT, whether currently or in the past, had fall rates well over twice as high as men never exposed to ADT, who had similar fall rates to that reported in a large population-based sample of similarly aged men. 25 It was also recently reported that Taiwanese men with prostate cancer taking ADT were twice as likely to have a fall as those not taking ADT, 26 but that study was unable to control for potential differences in disease severity and did not differentiate between current and past ADT users. The current study was able to confirm that ADT independently predicted falls and that stopping ADT may not ameliorate fall risk. A particularly salient finding of the current study was the high proportion of recurrent fallers among men taking ADT. Between 22% and 24% of current and past ADT users were recurrent fallers, compared with 5% of never users, which is comparable to the 6% reported for recurrent fallers in the broader population of older men. 25 Recurrent falls lead to higher rates of nursing home admission and mortality and worse quality of life than single falls 19, 27 and may be a symptom of frailty and poor physical and mental health status. 28, 29 When regression models were adjusted for disease severity, treatment, and age, current or past ADT users had a likelihood of recurrent falls that was six times as high as that of never users, and frailty or obese frailty was associated with odds of falling that were three to four times as high as no frailty. These findings strongly suggest that ADT is not merely a proxy indicator of disease severity or overall health status, but has an independent influence on fall risk, potentially through frailty. Frailty has been linked to higher falls risk, particularly recurrent falls, in older women and men. 30 In fully adjusted models, the odds of being a faller or recurrent faller were two to three times as high in men at risk of frailty (prefrail) or with frailty using the traditional phenotype and even higher odds ratios when considering obese frailty. Obese frailty may be a better predictor of falls in the current study sample than traditional frailty because obese captures the weakness associated with ADT-induced sarcopenia but also captures excess adiposity that is linked to poor balance. 24, 31 Based on these findings, men taking ADT should be monitored for early-onset fall and frailty risk and for recurrent falls, which increase the odds of a fall-related All models were adjusted for age; time since diagnosis; disease severity; and receipt of surgery, radiation therapy, or chemotherapy. injury. 32 Men exposed to ADT had significantly more injurious falls than those not undergoing treatment. These findings are similar to those tracked through adverse event reports in recent clinical trials of new androgen inhibitors, in which men taking additional second-line ADT agents (e.g., abiraterone, enzalutamide) were more likely to have a fall result in an injury including fracture, joint injury, and hematoma than men taking a single ADT agent plus a placebo. 5, 6, 33 Another new finding in the current study was that the rate of falls and frailty were similar in men who had received ADT within the last 12 months and those who had undergone ADT treatment further out. Although men with metastatic prostate cancer are most likely to receive continuous treatment with ADT, men treated for locoregional disease may be prescribed ADT for a finite period of time after adjuvant therapy, and men with biochemical recurrence may be placed on an intermittent regimen of ADT to balance prostate-specific antigen suppression with symptom relief. 2 The data from the current study indicate that past use of ADT confers a risk of falls and frailty similar to that of current use, suggesting that there may be little reversal of the body composition changes, fatigue, and mobility deficits that begin with initiation of androgen suppression. Although the survey focused on capturing prior or current ADT use rather than frequency of ADT dosing, the data suggest that cessation of ADT may not ameliorate side effects enough to alter long-term fall and frailty risk. Until future prospective studies that follow falls and frailty throughout varying courses of ADT are conducted, oncologists and primary care providers may wish to assess and monitor for falls and frailty risk in individuals with a history of ADT exposure.
This cross-sectional survey-based study had limitations, including the inability to establish causation between ADT use and falls or frailty. A survey approach was used to obtain a reasonable sample size to evaluate falls, which may have led to over or underreporting of outcomes, though cancer history and ADT use were verified using electronic medical records. Accurate data on the duration of and compliance with ADT were more difficult to extract from the medical record, thus these measures were not included in the analysis. Falls data in large samples are always obtained according to self-report, but the retrospective reporting of falls may result in underreporting of overall prevalence that would be independent of ADT use. Though disease severity was controlled for in analyses, the possibility that cancer itself influences fall and frailty risk cannot be ignored because ADT is prescribed to men whose cancer has progressed. A future prospective falls study would offer the advantage of linking the occurrence of falls to timing and trajectories of ADT use, disease progression, and fall risk factors. Frailty was also self-reported in this study using a validated survey [20] [21] [22] but is often assessed using a combination of self-report and performance-based measures. Men may have minimized their limitations and thus underreported frailty, but this bias would be expected to be similar across ADT groups. In addition, testosterone levels were not measured, and past ADT users were not distinguished according to duration of exposure, although 12 months without ADT is regarded as sufficient for recovery of testosterone. 34 It is possible that subsets of men who are exposed to a short course ADT and recover their testosterone levels return to a pretherapy level of fall risk, and this could be evaluated in future studies.
In summary, these findings provide evidence that ADT is associated with higher risk of falls, recurrent falls, frailty, and obese frailty and that risk for these poor health outcomes does not diminish when ADT is discontinued. These findings have important implications for the clinical management of men exposed to ADT for prostate cancer Model 1 a in oncology and general practice settings. Clinicians may consider evaluating men receiving ADT currently or in the past for fall risk using current fall prevention guidelines 32 and screen for frailty using the FRAIL scale or simple clinical assessments such as chair rise and sit, usual walk speed, presence of fatigue, and BMI. There have not been any trials of any strategy to reduce falls or the frailty phenotype in PCSs because these problems have not been well recognized or sufficiently characterized. Strategies such as exercise could prevent or reverse frailty related to ADT, interrupting the downward trajectory toward disability and dependence, and several studies have shown that exercise can improve individual frailty components in PCSs undergoing ADT, 35 such as leg strength and muscle mass; but it is not known whether and what type of exercise can change frailty components enough to reduce overall frailty status. The optimal timing of exercise training to prevent falls and frailty in PCSs while optimally managing their disease with ADT also needs to be understood.
